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Proteomic analysis of cortical neuronal
cultures treated with poly-arginine peptide-
18 (R18) and exposed to glutamic acid
excitotoxicity
Gabriella MacDougall3,4* , Ryan S. Anderton1,3,4, Frank L. Mastaglia1,3, Neville W. Knuckey1,2,3 and
Bruno P. Meloni1,2,3
Abstract
Poly-arginine peptide-18 (R18) has recently emerged as a highly effective neuroprotective agent in experimental
stroke models, and is particularly efficacious in protecting cortical neurons against glutamic acid excitotoxicity.
While we have previously demonstrated that R18 can reduce excitotoxicity-induced neuronal calcium influx, other
molecular events associated with R18 neuroprotection are yet to investigated. Therefore, in this study we were
particularly interested in protein expression changes in R18 treated neurons subjected to excitotoxicity.
Proteomic analysis was used to compare protein expression patterns in primary cortical neuronal cultures subjected
to: (i) R18-treatment alone (R18); (ii) glutamic acid excitotoxic injury (Glut); (iii) R18-treatment and glutamic acid
injury (R18 + Glut); (iv) no treatment (Cont). Whole cell lysates were harvested 24 h post-injury and subjected to
quantitative proteomic analysis (iTRAQ), coupled with liquid chromatography-tandem mass spectrometry (LC-MS/
MS) and subsequent bioinformatic analysis of differentially expressed proteins (DEPs).
Relative to control cultures, R18, Glut, and R18 + Glut treatment resulted in the detection of 5, 95 and 14 DEPs
respectively. Compared to Glut alone, R18 + Glut revealed 98 DEPs, including 73 proteins whose expression was also
altered by treatment with Glut and/or R18 alone, as well as 25 other uniquely regulated proteins. R18 treatment
reversed the up- or down-regulation of all 73 Glut-associated DEPs, which included proteins involved in
mitochondrial integrity, ATP generation, mRNA processing and protein translation. Analysis of protein-protein
interactions of the 73 DEPs showed they were primarily associated with mitochondrial respiration, proteasome
activity and protein synthesis, transmembrane trafficking, axonal growth and neuronal differentiation, and
carbohydrate metabolism. Identified protein pathways associated with proteostasis and energy metabolism, and
with pathways involved in neurodegeneration.
Collectively, the findings indicate that R18 neuroprotection following excitotoxicity is associated with preservation
of neuronal protein profiles, and differential protein expression that assists in maintaining mitochondrial function
and energy production, protein homeostasis, and membrane trafficking.
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Introduction
A major pathophysiological mechanism responsible for is-
chaemic stroke injury is excitotoxicity, which is trigged by
the excessive release of the excitatory neurotransmitter
glutamic acid in response to reduced cerebral blood flow
and compromised ATP synthesis. Excitotoxicity initiates a
range of forward-feeding biochemical events known as the
‘ischaemic cascade’, which if not inhibited eventually lead
to neuronal death and cerebral infarction [1]. Further-
more, as glutamic acid is the most prominent excitatory
neurotransmitter in the CNS [2], the detrimental effects of
glutamic acid excitotoxicity also play a role in other acute
brain disorders such as traumatic brain injury and epi-
lepsy, as well as chronic neurodegenerative disorders, such
as Alzheimer’s disease (AD) [3, 4], Huntington’s disease
(HD) [5, 6], Parkinson’s disease (PD) [7, 8], and amyo-
trophic lateral sclerosis (ALS) [9, 10].
Despite ongoing research, neuroprotective therapies
for acute brain injuries and other neurodegenerative dis-
orders are either not available or are extremely limited
with modest efficacy. Recent studies in our laboratory
have identified cationic arginine-rich peptides (CARPs),
which include poly-arginine peptides, as a novel class of
neuroprotective agents. In particular, we have demon-
strated that poly-arginine-18 (R18, 18-mer of arginine) is
neuroprotective in in vitro neuronal excitotoxicity
models and in vivo in rodent models of stroke [11–18],
hypoxic-ischaemic encephalopathy (HIE) [19], and trau-
matic brain injury (TBI) [20, 21].
Given the neuroprotective properties of R18, it is im-
perative that the molecular pathways that underlie its
neuroprotective action are fully elucidated in order to
gauge its therapeutic potential. While we have previously
demonstrated that R18 has the capacity to reduce glu-
tamic acid-induced excitotoxic neuronal death and intra-
cellular calcium influx, and reduce neuronal NMDA
receptor levels [22], CARPs also have cell-penetrating
properties and can target mitochondria [23]. Therefore,
it is likely that R18 and other CARPs have additional
intracellular neuroprotective mechanisms of action. In
addition, it is also important to examine the ability of
R18 to preserve intracellular protein expression and bio-
chemical pathways following a neurodamaging insult. As
such, in this study we performed iTRAQ proteomics
and bioinformatic analysis (Fig. 1) of protein cell lysates
collected from primary cortical neuronal cultures sub-
jected to glutamic acid excitotoxicity with and without
treatment with R18.
Methods
Peptides
Poly-arginine-18 (R18; H-RRRRRRRRRRRRRRRRRR-
OH) was synthesized by Mimotopes (Australia) and
purified to 98% by HPLC. Peptides were prepared as
500 μM stocks in Baxter water (Australia) and stored at
− 20 °C prior to use.
Primary cortical neuronal cultures
Cortical neuronal tissue was extracted from E18
Sprague-Dawley rat embryos, dissociated, resuspended
in Neurobasal/2% B27 supplement (B27) and seeded at
approximately 55,000 cells/well into 96-well plates
(Nunc, Australia), pre-coated with poly-lysine (Sigma-
Aldrich Australia) as previously described [24]. Plates
were maintained at 37 °C in a CO2 incubator (95% air
balance, 98% humidity, 5% CO2) until use on day in vitro
10, when cultures routinely comprise > 97% neurons and
1–3% astrocytes. Approval for the use of E18 Sprague-
Dawley rat embryos for isolation of cortical tissue was
obtained by the University of Western Australia Animal
Ethics Committee (RA/3/100/1432).
Glutamic acid excitotoxicity model and assessment of cell
viability
Cortical neuronal cultures were subjected to glutamic
acid excitotoxicity and R18 treatment as previously
described [22]. R18 treatment consisted of adding the
peptide to culture wells 10 min prior to glutamic acid
(L-glutamic acid; Sigma-Aldrich) exposure by remov-
ing media and adding 50 μL of Minimal Essential
Media (MEM)/2% B27 containing peptide (2 μM). To
induce excitotoxicity, 50 μL of MEM/2% B27 contain-
ing glutamic acid (200 μM; final concentration
100 μM) was added to the culture wells and incubated
at 37 °C in the CO2 incubator for 5 min (note: peptide
concentration reduced to 1 μM during this step). Fol-
lowing the 5-min exposure, media was replaced with
100 μL of MEM/2% B27 and cultures incubated for a
further 24 h at 37 °C in the CO2 incubator. Untreated
controls with or without glutamic acid treatment
underwent the same incubation steps and media
additions.
At 24 h post-injury, cell viability was assessed qualita-
tively by light microscopy, and quantitatively using the
CellTiter 96 Aqueous Cell Proliferation MTS assay (Pro-
mega, Australia), which determines metabolic capacity
of cells through the reduction of the tetrazolium salt
(MTS), forming a brown formazan salt that is measured
spectrophotometrically at 490 nm.
Protein extraction
At 24 h post-injury, cells were lysed with 20 μL/well of
RIPA buffer (mM: 150 NaCl, 5 EDTA, 50 Tris; %: 1.0
NP-40, 0.5 sodium deoxycholate, 0.1 SDS; pH 8.0) con-
taining protease and phosphatase inhibitor cocktail
(Roche Applied Science, Australia). Cell lysates from 8
wells within the same plate were pooled, and this was re-
peated four times with independent neuronal cultures.
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Lysates were clarified by centrifugation at 14,000 g for 5
min at 4 °C, and protein concentration determined via
Bradford’s assay (Bio-Rad). Aliquots (3.5 mg/mL) of each
treatment group were prepared for subsequent iTRAQ
analysis and stored at − 20 °C prior to use.
Protein sample preparation and iTRAQ labelling
Quantitative 4-plex iTRAQ proteomics analysis was
performed on four independent protein samples for
each treatment. Protein sample preparation and
iTRAQ labeling was as previously described [25].
Briefly, the protein samples were de-salted, reduced,
alkylated, and trypsin-digested according to the
iTRAQ protocol [Sciex]. The resulting peptide sam-
ples were labeled with iTRAQ reagents as follows:
114: Untreated control (Cont); 115: glutamic acid
treated (Glut); 116: R18 treated (R18); 117: R18 and
glutamic acid treated (R18 + Glut). All labeled sam-
ples were combined to make a pooled sample. Pep-
tides were desalted on a Strata-X 33 μM polymeric
reversed phase column (Phenomenex) and dissolved
in a buffer containing 2% acetonitrile 0.1% formic
acid before separation by High pH on an Agilent
1100 HPLC system using a Zorbax C18 column
(2.1 × 150 mm). Peptides were eluted with a linear
gradient of 20 mM ammonium formate, 2% ACN to
20 mM ammonium formate, 90% ACN at 0.2 mL/
min. The 95 fractions were concatenated into 12
fractions and dried down. Each fraction was analyzed
by electrospray ionization mass spectrometry using
the Shimadzu Prominence nano HPLC system [Shi-
madzu] coupled to a 5600 TripleTOF mass spec-
trometer [Sciex]. Samples were loaded onto an
Agilent Zorbax 300SB-C18, 3.5 μm [Agilent Tech-
nologies] and separated with a linear gradient of
water/acetonitrile/0.1% formic acid (v/v). Fourteen
percent of the labeled sample was loaded on the
mass spectrometer.
Proteomic data analysis: qualification and quantitation
Spectral data was qualified using ProteinPilot™ 5.0 soft-
ware [Sciex] against the SwissProt database, utilizing the
Fig. 1 Summary diagram of experimental flow, with the three key processes highlighted by different colours. These broadly include the initial cell
treatment and protein collection (red); protein processing, purification, iTRAQ labelling, and quantification for each sample (blue); and analysis of
bioinformatics data (grey). DEPs = differentially expressed proteins; LC-MS/MS = liquid chromatography-tandem mass spectrometry
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Rattus norvegicus (Rat) taxonomy (Version: April 2017,
7,985 sequences; https://www.uniprot.org/proteomes/
UP000002494). The False Discovery Rate (FDR) was
automatically calculated by the Proteomics System
Performance Evaluation Pipeline (PSPEP) feature in the
ProteinPilot™ software (AB Sciex, Foster, CA, USA;
Version 5.0.1) using the reversed version of the protein
sequences contained in the search database. For quanti-
tative protein analysis, a fold change in protein expres-
sion > ±1.3-fold with a p < 0.05 was considered to be a
‘differentially expressed protein’ (DEP). Protein expres-
sion changes with R18, Glut, and R18 + Glut treatment
were compared to the control (Cont). In addition, pro-
tein changes with Glut treatment were compared with
R18 + Glut treatment using Cont protein expression as
baseline.
Proteomic data analysis: bioinformatics
Gene ontology analysis with the ‘Protein ANalysis
THrough Evolutionary Relationships’ (PANTHER; Ver-
sion 14.0, released 2018-12-03; http://pantherdb.org/)
classification system was utilized to categorize the col-
lective DEPs in the R18, Glut, or R18 + Glut samples,
relative to Cont sample, as well as Glut sample, relative
to the Glut + R18 sample. These proteins were function-
ally categorized according to the domains of ‘biological
processes’, ‘molecular functions’, and ‘cellular compo-
nents’ [26].
Protein-protein interaction networks were identified
using STRING (Version 11.0, released 2017-05-14;
http://www.string-db.org/). STRING is a database of
known and predicted physical and functional protein-
protein interaction, generated through computational
prediction from five key databases: ‘Genomic Context
Predictions’, ‘High-throughput Lab Experiments’, ‘(Con-
served) Co-Expression’, ‘Automated Textmining’, and
‘Previous Knowledge in Databases’. Cytoscape (Ver-
sion 3.7.1) was subsequently utilized to construct and
analyze the protein-protein interaction networks, and
‘Cluster with overlapping Neighbourhood Expansion’
(Cluster ONE; Version 14) was used for network clus-
tering of protein-protein interactions, to identify
densely connected and overlapping protein networks.
Identified DEPs were also imported into the Kyoto
Encyclopedia of Genes and Genomes (KEGG) Pathway
database (http://www.genome.jp/kegg/pathway.html) for
analysis of common biological pathways and diseases as-
sociated with the DEPs.
Statistical analysis
Statistical analysis was conducted with the Prism 8.0
GraphPad statistical software package. Cell viability
data were expressed as mean ± S.E.M. of biological
replicates, and multiple comparisons were conducted
with one-way ANOVA and Bonferroni’s post hoc test
to assess significance, with significance taken as p < 0.05.
For Cytoscape network analysis, network cut-offs of > 3
proteins were utilized, and a one-sided Mann-Whitney U
test was used to identify significant common networks
(p < 0.05).
Results
R18 improves cell viability in uninjured and glutamic
acid-treated neuronal cells
In line with previous studies [12], R18 exhibited potent
neuroprotection against glutamic excitotoxic injury in
cortical neuronal cultures. In addition, as has been previ-
ously reported, cell viability was also significantly in-
creased in neuronal cultures treated with R18 compared
to control cultures (Fig. 2).
Quantitative and qualitative proteomic analysis
iTRAQ proteomic analysis detected 7,528 distinct pep-
tide fragments with > 95% confidence, resulting in the
identification of 800 proteins (minimum of ≥2 matching
peptide hits with > 95% confidence) consisting of a total
of 140 distinct proteins (Table 1 and Additional file 1:
Table S1). When compared to Cont, R18, Glut, and Glut
+ R18 differentially regulated 5, 95 and 14 proteins, re-
spectively (Table 1; see Additional file 2: Table S2 for
Glut + R18 DEPs). When compared to Glut, R18 + Glut
differentially regulated 98 proteins (Table 1 and Add-
itional file 2: Table S2).
Fig. 2 R18 provides potent neuroprotection against glutamic acid
excitotoxicity in primary cortical neurons. Neuronal cultures were
subjected to a 10-min R18 pre-treatment (2 μM) and subsequent 5-
min glutamic acid exposure (Glut; 100 μM). MTS cell viability was
assessed at 24 h post-injury. Cell viability was expressed as mean ±
S.E.M (p < 0.05 relative to *Glut or #Cont)
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Table 1 Differentially expressed proteins identified in neurons treated with: R18 (R18), glutamic acid (Glut), or R18 and glutamic acid
exposure (R18 + Glut)
Gene name SwissProt
Accession
Number
Protein Fold up−/down-regulateda
R18 vs Cont Glut vs Cont R18 + Glut vs Glut
Mitochondrial respiration/function
Acly P16638 ATP-citrate synthase 1.076 −2.399b 1.659
Aco2 Q9ER34 Aconitate hydratase, mitochondrial −1.028 −3.435 4.285
Atp5a1 P15999 ATP synthase subunit alpha, mitochondrial −1.472 1.888 −2.421
Atp5b P10719 ATP synthase subunit beta, mitochondrial −1.117 2.558 −3.342
Atp5h P31399 ATP synthase subunit d, mitochondrial 1.076 2.754b −1.836
Atp5o Q06647 ATP synthase subunit O, mitochondrial 1.406 2.032b −1.644
Cat P04762 Catalase −1.555 1.138 −1.659b
Cox4i1 P10888 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial −1.259 2.070 −2.704
Idh1 P41562 Isocitrate dehydrogenase [NADP] cytoplasmic 1.066 1.459 −1.486
Mdh2 P04636 Malate dehydrogenase, mitochondrial −1.247 2.355 −2.535
Ndufs1 Q66HF1 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial 1.294 2.443 −5.249
Uqcrc2 P32551 Cytochrome b-c1 complex subunit 2, mitochondrial −1.247 1.888 −2.704
Proteasome & Protein synthesis
Asns P49088 Asparagine synthetase [glutamine-hydrolyzing] 2.089 2.228 2.421b
Cct2 Q5XIM9 T-complex protein 1 subunit beta 1.106 −3.802 3.631
Cct3 Q6P502 T-complex protein 1 subunit gamma −1.158 −4.787 4.207
Cct4 Q7TPB1 T-complex protein 1 subunit delta 1.127 −3.944 3.499
Cct5 Q68FQ0 T-complex protein 1 subunit epsilon 1.096 −2.269 2.291
Psmc1 P62193 26S protease regulatory subunit 4 −1.419 −22.67 18.197
Axonal growth/Neuronal differentiation/Cytoskeletal arrangement
Actr2 Q5M7U6 Actin-related protein 2 −1.355 − 1.271 − 1.459b
Ap2m1 P84092 AP-2 complex subunit mu 1.271 −5.394 6.855
Armc10 B1WBW4 Armadillo repeat-containing protein 10 −1.294 −6.667 2.070
Baiap2 Q6GMN2 Brain-specific angiogenesis inhibitor 1-associated protein 2 −1.331 −90.09 99.083
Basp1 Q05175 Brain acid soluble protein 1 1.343 1.614 −1.270
Cntn1 Q63198 Contactin-1 −1.117 1.977 −1.836
Cttn Q66HL2 Src substrate cortactin 1.117 −5.345b 3.251
Dcx Q9ESI7 Neuronal migration protein doublecortin 1.000 −6.139 6.026
Dnm1 P21575 Dynamin-1 −2.148 −4.093 3.076
Dpysl2 P47942 Dihydropyrimidinase-related protein 2 −1.225 1.723 −1.690
Dync1h1 P38650 Cytoplasmic dynein 1 heavy chain 1 −1.087 −8.873 8.472
Fabp7 P55051 Fatty acid-binding protein, brain −1.028 4.406b −4.207
Fyn Q62844 Tyrosine-protein kinase Fyn 1.117 −2.489 2.754b
Gdi1 P50398 Rab GDP dissociation inhibitor alpha −1.419 1.820 −2.965
Gfap P47819 Glial fibrillary acidic protein 1.4322 1.906b −1.159
Kif21b F1M5N7 Kinesin-like protein KIF21B −1.282 −17.857 16.444
Krt1 Q6IMF3 Keratin, type II cytoskeletal −4.055b −1.236 −6.485
Krt10 Q6IFW6 Keratin, type I cytoskeletal 10 −2.168 −1.722 −16.892b
Map2 P15146 Microtubule-associated protein 2 1.138 −8.628 11.482
Map4 Q5M7W5 Microtubule-associated protein 4 −2.884 −4.488 4.169
Mapt P19332 Microtubule-associated protein tau 1.077 −7.179 7.379
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Table 1 Differentially expressed proteins identified in neurons treated with: R18 (R18), glutamic acid (Glut), or R18 and glutamic acid
exposure (R18 + Glut) (Continued)
Gene name SwissProt
Accession
Number
Protein Fold up−/down-regulateda
R18 vs Cont Glut vs Cont R18 + Glut vs Glut
Myh10 Q9JLT0 Myosin-10 −1.459 −2.466 2.228
Ncam1 P13596 Neural cell adhesion molecule 1 −1.180 2.831 −4.093
Pa2 g4 Q6AYD3 Proliferation-associated protein 2G4 1.202 −2.188 2.489b
Pak3 Q62829 Serine/threonine-protein kinase PAK 3 −2.208 −4.365 5.754b
bPebp1 P31044 Phosphatidylethanolamine-binding protein 1 1.5276 2.780b −2.128
Rala P63322 Ras-related protein Ral-A −1.236 2.704b −1.690
Rtn4 Q9JK11 Reticulon-4 1.107 −2.148 2.679
Tpm4 P09495 Tropomyosin alpha-4 chain −1.097 −2.270 1.738b
Tuba4a Q5XIF6 Tubulin alpha-4A chain 1.086 −2.679b 2.535
Tubb5 P69897 Tubulin beta-5 chain −1.038 −18.018 16.444
Vesicular/Transmembrane trafficking
Actn4 Q9QXQ0 Alpha-actinin-4 −1.294 1.906b −1.381
Actr1a P85515 Alpha-centractin −1.738 −3.565b 2.148
Ap2a2 P18484 AP-2 complex subunit alpha-2 1.159 −2.582 3.698b
Atp1a3 P06687 Sodium/potassium-transporting ATPase subunit alpha-3 −2.128 1.660 −2.355
Cadps Q62717 Calcium-dependent secretion activator 1 −1.486 −11.481 6.194
Camk2a P11275 Calcium/calmodulin-dependent protein kinase type II subunit alpha −1.419 −6.667 6.918
Cask Q62915 Peripheral plasma membrane protein CASK 1.514 1.306 −1.888b
Dpysl5 Q9JHU0 Dihydropyrimidinase-related protein 5 −1.180 1.213 −1.459b
Klc1 P37285 Kinesin light chain 1 1.107 −6.024b 5.058
Nsf Q9QUL6 Vesicle-fusing ATPase −1.117 −5.807 4.656
Prkar2b P12369 cAMP-dependent protein kinase type II-beta regulatory subunit −1.472 −3.105 1.754
Stx1b P61265 Syntaxin-1B 1.225 1.600 −1.419
Stxbp1 P61765 Syntaxin-binding protein 1 −1.107 1.600 −2.466
Syn1 P09951 Synapsin-1 −1.786 −3.597b 3.3113
ER proteostasis/Protein modification
Calr P18418 Calreticulin 1.419 1.871 −1.570
Ddost Q641Y0 Oligosaccharyl transferase 48 kDa subunit −1.500 2.466 −2.938
Erp29 P52555 Endoplasmic reticulum resident protein 29 −1.067 2.168b −3.163
Hsp90aa1 P82995 Heat shock protein HSP 90-alpha 1.038 1.282 −1.446b
Hspa5 P06761 78 kDa glucose-regulated protein 1.038 2.014 −1.542
Hspa8 P63018 Heat shock cognate 71 kDa protein 1.259 −2.208 2.559b
Hspa9 P48721 Stress-70 protein, mitochondrial 1.159 −6.083 8.318
Hspd1 P63039 60 kDa heat shock protein, mitochondrial 1.107 1.486 −1.556
Pdia3 P11598 Protein disulfide-isomerase A3 −1.600 1.614 −1.995
Phb P67779 Prohibitin −1.213 1.644 −2.535
Phb2 Q5XIH7 Prohibitin-2 −1.047 3.837 −2.992
Por P00388 NADPH--cytochrome P450 reductase −1.107 −1.038 1.343b
Tcp1 P28480 T-complex protein 1 subunit alpha −1.472 −3.597b 2.911
Uba1 Q5U300 Ubiquitin-like modifier-activating enzyme 1 −1.107 −5.105 4.406
Glycolysis & Carbohydrate metabolism
Alb P02770 Serum albumin −1.570 1.722 −5.701
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Table 1 Differentially expressed proteins identified in neurons treated with: R18 (R18), glutamic acid (Glut), or R18 and glutamic acid
exposure (R18 + Glut) (Continued)
Gene name SwissProt
Accession
Number
Protein Fold up−/down-regulateda
R18 vs Cont Glut vs Cont R18 + Glut vs Glut
Aldoa P05065 Fructose-bisphosphate aldolase A −1.660 1.629 −2.355
Eno1 P04764 Alpha-enolase 1.107 2.911 −1.706
Gapdh P04797 Glyceraldehyde-3-phosphate dehydrogenase −1.028 −11.700 10.280
Gpi Q6P6V0 Glucose-6-phosphate isomerase −1.318 1.754 −3.435
Hk1 P05708 Hexokinase-1 1.138 2.051b −1.888
Ldha P04642 L-lactate dehydrogenase A chain −1.786 1.028 −1.675b
Pkm P11980 Pyruvate kinase PKM −1.009 1.787 −1.941
Taldo1 Q9EQS0 Transaldolase 1.259 −1.837 2.109
Mitochondrial fatty acid synthesis
Acat1 P17764 Acetyl-CoA acetyltransferase, mitochondrial 1.159 2.377 −1.500
Bdh1 P29147 D-beta-hydroxybutyrate dehydrogenase, mitochondrial −1.213 −5.970 4.246
Fasn P12785 Fatty acid synthase −1.117 −3.311 2.704
Got2 P00507 Aspartate aminotransferase, mitochondrial −1.923 1.213 −2.109b
Ribosome components/RNA trafficking & processing
Aars P50475 Alanine--tRNA ligase, cytoplasmic −1.556 −5.495 4.699
C1qbp O35796 ASF/SF2-associated protein p32 1.213 1.600b −1.888
Ddx1 Q641Y8 ATP-dependent RNA helicase DDX1 −1.148 −11.173 4.286
Eef1a1 P62630 Elongation factor 1-alpha 1 −1.225 −5.444 4.529
Eef2 P05197 Elongation factor 2 −1.202 −4.131 3.048
Eif4a2 Q5RKI1 Eukaryotic initiation factor 4A-II −1.057 −3.945 3.02
Eif5a Q3T1J1 Eukaryotic translation initiation factor 5A-1 1.514 −6.983 9.638
Elavl2 Q8CH84 ELAV-like protein 2 −1.107 −4.405 5.598b
Hnrnpa1 P04256 Heterogeneous nuclear ribonucleoprotein A1 −1.076 −9.911 9.462
Hnrnpa2b1 A7VJC2 Heterogeneous nuclear ribonucleoproteins A2/B1 1.318 −4.325 6.138
Hnrnpa3 Q6URK4 Heterogeneous nuclear ribonucleoprotein A3 1.191 −3.311 4.920
Hnrnpd Q9JJ54 Heterogeneous nuclear ribonucleoprotein D0 1.202 −5.495 6.252
Hnrnpk P61980 Heterogeneous nuclear ribonucleoprotein K −1.057 −8.091 8.872
Hnrnpl F1LQ48 Heterogeneous nuclear ribonucleoprotein L −1.028 −2.729 4.207b
Khsrp Q99PF5 Far upstream element-binding protein 2 1.556 −3.908 8.017b
Matr3 P43244 Matrin-3 −1.500 −3.373b 3.945
Rpl7 P05426 60S ribosomal protein L7 1.225 −2.109 2.188b
Rpl13 P41123 60S ribosomal protein L13 −1.057 −2.377 2.754b
Rplp0 P19945 60S acidic ribosomal protein P0 1.486b −1.191 −1.076
Rps24 P62850 40S ribosomal protein S24 1.854 −5.754 14.06b
Rps27 Q71TY3 40S ribosomal protein S27 −1.102 −18.18b 5.058
Yars Q4KM49 Tyrosine--tRNA ligase, cytoplasmic −1.225 −4.656 3.342
Calcium transport and signalling
Vdac1 Q9Z2L0 Voltage-dependent anion-selective channel protein 1 −1.419 2.466 −2.938
Cacna2d1 P54290 Voltage-dependent calcium channel subunit alpha-2/delta-1 1.306 4.207 −4.018
Gnao1 P59215 Guanine nucleotide-binding protein G(o) subunit alpha −1.148 −5.152 3.802
Letm1 Q5XIN6 LETM1 and EF-hand domain-containing protein 1, mitochondrial −3.020 1.459b −1.236
Nudt3 Q566C7 Diphosphoinositol polyphosphate phosphohydrolase 1 1.459b 1.282 1.117
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Proteins regulated by R18 treatment alone (R18 vs Cont)
Of the five DEPs identified in the R18 sample, three
were uniquely regulated (Table 1). Two of these proteins
were upregulated: 60S acidic ribosomal protein P0
(Rplp0; 1.49) and Diphosphoinositol polyphosphate
phosphohydrolase 1 (Nudt3; 1.46), and one was down-
regulated: keratin, type II cytoskeletal (Krt1; − 4.05).
Proteins regulated by glutamic acid injury alone (glut vs Cont)
Of the 95 DEPs identified in the Glut sample, 21 were
uniquely regulated (Table 1). The greatest magnitude
fold-change in a down-regulated protein was observed
for brain-specific angiogenesis inhibitor 1-associated
protein 2 (Baiap2; − 90.09), while the greatest fold-
change in an up-regulated protein was for fatty acid-
binding protein, brain (Fabp7; 4.41).
Proteins regulated by R18 plus glutamic acid injury (R18 +
Glut vs Cont)
Of the 14 DEPs identified in the R18 + Glut sample none
were uniquely regulated (Additional file 2: Table S2).
The greatest magnitude fold-change in an up-regulated
protein was observed for UV excision repair protein
RAD23 homolog B (Rad23b; 3.251), while the greatest
fold-change in a down-regulated protein was for Keratin,
type I cytoskeletal 10 (Krt10; − 33.333).
Proteins regulated by R18 plus glutamic acid injury vs
glutamic acid injury alone (R18 + Glut vs glut)
Of the 98 DEPs identified after R18 + Glut treatment
(R18 + Glut vs Glut), 73 of the proteins were also regu-
lated by R18 and/or Glut treatments alone, and 25 were
uniquely regulated (Table 1; uniquely regulated proteins
indicated by *). In addition, R18 treatment reversed the
up- or down-regulation of all 73 DEPs (Table 1, Fig. 3).
Of the 25 uniquely regulated proteins, the greatest mag-
nitude fold-change in protein expression observed was
with Brain-specific angiogenesis inhibitor 1-associated
protein 2 (Baiap2; − 99.08).
Functional categorization of differentially regulated
proteins (DEPs)
For further functional characterization of DEPs we fo-
cused on protein changes in the R18 and R18 + Glut
treatments groups as we were most interested in the ef-
fects of R18 on proteins regulated in uninjured and in-
jured neurons. PANTHER Gene Ontology analysis was
utilized to categorize the DEPs regulated by R18 alone (5
proteins; R18 vs Cont), and the DEPs regulated by
R18 + Glut treatment (73 proteins; R18 + Glut vs Glut)
according to ‘cellular component’ (Fig. 4a and d) ‘bio-
logical process’ (Fig. 4b and e), and ‘molecular function’
(Fig. 4c and f) (Full data provided in Additional file 3:
Table S3).
The 5 DEPs regulated by R18 treatment included pro-
teins located in the nucleus and ribosomes which
catalyze purine nucleotide catabolic activity (e.g. Nudt3),
and modulate rRNA binding (e.g. Rplp0). Other proteins
regulated by R18 are involved in intracellular ion traf-
ficking (e.g. Atp1a3) and cytoskeletal structure (e.g.
Krt1) (Table 1).
The 73 DEPs regulated by R18 + Glut treatment in-
cluded proteins involved in mitochondrial respiration
and function (e.g. Aco2 and Atp5a1), proteasomal regu-
lation and protein synthesis (e.g. Psmc1 and Cct3), pro-
teostasis/protein modification in the endoplasmic
reticulum (e.g. Hspa9 and Uba1), and RNA trafficking/
processing (e.g. Eif5a and Hnrnpa1), as well as cytoskel-
etal rearrangement and axonal growth (e.g. Map2 and
Dcx) and vesicular/membrane trafficking (e.g. Atp1a3
and Camk2a). Significant changes of key neuronal pro-
teins are summarized in the schematic detailed in Fig. 5
(full data available in Additional file 2: Table S2 and
Additional file 3: Table S3).
Protein-protein interaction network analysis of DEPs
regulated by R18 in uninjured and glutamic acid injured
neurons
STRING analysis was used to identify potential protein-
protein interactions across the 5 DEPs regulated by R18
Table 1 Differentially expressed proteins identified in neurons treated with: R18 (R18), glutamic acid (Glut), or R18 and glutamic acid
exposure (R18 + Glut) (Continued)
Gene name SwissProt
Accession
Number
Protein Fold up−/down-regulateda
R18 vs Cont Glut vs Cont R18 + Glut vs Glut
Ywhaq P68255 14–3-3 protein theta −1.087 1.355 −1.615
Miscellaneous
Ak1 P39069 Adenylate kinase isoenzyme 1 (Cellular energy homeostasis) 1.009 −2.938 4.325
Atic O35567 Bifunctional purine biosynthesis protein PURH (Purine biosynthesis) 1.038 1.923 −2.630b
Dnm1l O35303 Dynamin-1-like protein (Mitochondrial fission) −1.820 −7.519b 5.297
Hist1h4b P62804 Histone H4 (Transcription regulation) 1.754 −3.802 7.516b
a Statistically significant values (p < 0.05) for fold up−/down-regulation ≥1.3-fold are highlighted in bold. b 25 uniquely DEPs in R18 and Glut treatment versus
Cont, or R18 + Glut treatment versus Glut
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treatment, and the 73 DEPs regulated by Glut and
R18 + Glut. No significant protein-protein interactions
were identified for the 5 DEPs regulated by R18 treat-
ment (R18 vs Cont) (Fig. 6a). Two hundred and
twenty-two nodes representing direct and indirect
protein-protein interactions were identified for the 73
DEPs regulated by R18 + Glut treatment (R18 + Glut
vs Glut) (Fig. 6b).
ClusterONE network analysis of the 222 nodes re-
vealed that the protein-protein interactions could be
grouped into eight clusters representing distinct bio-
logical functional entities (Fig. 7; boxed proteins). The
clusters were classified as ‘Mitochondrial respiration’
(55 nodes), ‘Proteasome and Protein synthesis’ (43
nodes), ‘Axonal growth & neuronal differentiation’ (11
nodes), ‘Transmembrane trafficking’ (10 nodes), ‘Endo-
plasmic reticulum proteostasis’ (8 nodes), ‘Glycolysis
and carbohydrate metabolism’ (7 nodes), ‘RNA traf-
ficking and processing’ (4 nodes), and ‘Mitochondrial
fatty acid synthesis’ (4 nodes) (Full data provided in
Additional file 4: Table S4).
KEGG pathway analysis of 73 shared proteins
KEGG pathway analysis to determine the biological
pathways and diseases associated with 222 protein-
protein interactions identified pathways pertaining to
proteostasis (‘Proteasome’; 34 of 46 proteins), energy
metabolism (‘Oxidative phosphorylation’; 52 of 130
proteins), and neurotransmission (‘Synaptic vesicle
cycle’; 14 of 60 proteins), and ‘Retrograde endocanna-
binoid signaling’; 34 of 144 proteins) (Fig. 8; full data
in Additional file 5: Table S5). In addition, KEGG
analysis revealed that the protein-protein interactions
were associated with the neurodegenerative disorders
Parkinson’s disease (PD; 52 of 134 proteins), Alzhei-
mer’s disease (AD; 47 of 164 proteins), and Hunting-
ton’s disease (HD; 50 of 181 proteins).
Discussion
In recent years, CARPs have emerged as a novel class of
potential neuroprotective therapeutics for a broad range
of acute brain injuries and chronic neurodegenerative
disorders. These CARPs include short-chained poly-
arginine peptides [11, 13, 27], SS-peptides [28, 29],
APOE-derived peptides [27, 30], and TAT-fused pep-
tides, including TAT-NR2B9c (NA-1) and JNK1-TAT
[11, 31]. Such CARPs have been shown to exert their
neuroprotective action through a variety of targets,
which include structural and functional preservation of
mitochondria [32], reduced ROS generation [33], inhib-
ition of protein aggregation [34], modulation of
glutamate or calcium ion receptors (excitotoxicity/cal-
cium influx) [35], and activation of pro-survival signaling
[36, 37]. Given the diverse biochemical and cellular ef-
fects CARPs can exert on cells, it is likely that other
cytoprotective processes are also involved, which have
yet to be fully elucidated. To this end, the present study
is the first to employ an iTRAQ proteomics approach to
gain insight into protein expression changes after poly-
arginine-18 (R18) treatment of uninjured neuronal cul-
tures and neuronal cultures subjected to glutamic acid
excitotoxic injury.
Fig. 3 Heatmap of differentially expressed proteins (DEPs) regulated
by R18 vs Cont, Glut vs Cont, or R18 + Glut vs Glut. Protein
expression changes are shown as log(2) of fold-change
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The effects of R18 treatment on uninjured neurons
Proteomics analysis of neuronal cultures 24-h after a
10-min exposure to R18 identified 5 DEPs. The small
number of detected protein expression changes was
surprising given that CARPs can induce a variety of
biological effects on cells [38]. However, it is likely
that the small number of proteins detected was in
part due to the 24-h post-R18 treatment time point
used to analyze protein expression changes, as major-
ity of the protein changes elicited by R18 treatment
may potentially occur within the first few hours, and
as such, may no longer have been detectable or did
A
B
C
D
E
F
Fig. 4 PANTHER gene-ontology functional categorization of DEPs regulated by R18 in healthy neurons (vs Cont; blue), and R18 + Glut in injured
neurons (vs Glut; red). The top five categories are displayed across the functional categories of (a, b) Molecular Function (c, d) Biological Process,
and (e, f) Cellular Component
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not fit the requirements for classification of a DEP
(e.g. ± > 1.3 fold change) by 24 h.
The proteins that were identified as being affected
by R18 were largely associated with protein synthesis
and transmembrane protein and cationic ion trans-
port, and did not significantly map onto KEGG path-
ways, suggesting that the R18 peptide does not exert
long-term biological effects in uninjured neurons.
This is in line with the proposed notion that neuro-
protective agents should preferentially interact with
and/or modulate cellular targets activated following
pathological events to minimize the chance of off-
target side effects. Such protective agents are
deemed ‘pathologically-activated’ therapeutics, which
are thought to have a particularly useful application
in neurological disorders, as brain tissue is especially
susceptible to drug-induced disruptions and un-
wanted drug side-effects [38, 39]. However, to pro-
vide a more comprehensive assessment of the
biological effects of R18 on uninjured neurons, fu-
ture studies should examine protein expression at
earlier time points.
Fig. 5 Schematic representation of representative shared neuronal proteins regulated by glutamic acid excitotoxicity (Glut) and R18 + Glut, based
on location and function. Comprehensive protein changes are detailed in Table 1
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R18 treatment reduces glutamic acid-induced changes in
protein expression
An important finding of this study was the ability of
R18 treatment to reverse the majority (74.5%; 73 of
98) of the protein changes induced by glutamic acid
excitotoxicity, and thereby preserve the protein ex-
pression profiles of cortical neurons post-insult (Table
1; Additional file 4: Table S4). Further analysis re-
vealed that these protein changes underpin key cellu-
lar functions, such as mitochondrial respiration and
energy production, proteostasis, neuronal transmem-
brane trafficking, and RNA processing, which are
dysregulated by excitotoxicity. Moreover, KEGG ana-
lysis of protein-protein interactions indicated predom-
inant involvement of pathways pertaining to the
proteasome and oxidative phosphorylation, which also
represent two central biological processes underpin-
ning aspects of neurodegenerative pathophysiology.
This likely contributed to the identification of
enriched protein-protein interactions pertaining to
Parkinson’s disease, Alzheimer’s disease and Hunting-
ton’s disease.
Severe and/or prolonged disruptions in the ubiquitin-
proteasome system have been implicated in both acute
A
B
Fig. 6 Enriched STRING PPI network analysis of DEPs regulated by a. R18 treatment in healthy neurons (vs Cont), and b. DEPs commonly regulated by
Glut and R18 + Glut (vs Glut), demonstrating molecular actions of direct and indirect protein-protein interactions between significantly regulated
proteins. STRING parameters were set to high confidence (0.700), with only query proteins shown
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(ischaemic stroke, TBI) and chronic (AD, PD, motor
neuron disease) neurological disorders [39, 40]. Pre-
vious studies have shown that CARPs exhibit pro-
teasomal modulatory activity and could potentially
conserve protein expression profiles through inhib-
ition of injury-induced proteasomal protein
degradation. For example, the arginine-rich PR-11
(H-RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPR
FP-OH; net charge + 11) and PR-39 (H-RRRPRPPY
LPR-OH; net charge + 5) peptides attenuate inflam-
mation induced by ischaemia-reperfusion injury
through inhibition of proteasomal degradation of
IκBα; a NFκB inhibitory protein [41, 42]. Taken to-
gether, it appears CARPs can influence the function
of the proteasome, and thereby exert neuroprotec-
tive benefits during times of cellular stress.
Proteomic analysis also revealed that R18 preserved
protein expression profiles pertaining to mitochondrial
bioenergetics and structural integrity. Mitochondria are
central mediators of intracellular calcium signaling
events during excitotoxicity, and as such, are considered
the “judge, jury, and executioner” of the cell [31, 43].
During excitotoxic injury, mitochondria act as a buffer
for toxic intracellular calcium accumulation, however
excessive mitochondrial calcium uptake can disrupt their
structural and functional integrity, resulting in the re-
lease of pro-death signaling proteins from the mitochon-
drial inter-membrane space [44, 45]. Therefore, the
ability of R18 treatment to attenuate excitotoxicity-
induced protein changes underlying loss of mitochon-
drial integrity, provides evidence that the peptide helps
preserve the function of the organelle in times of cellular
stress. In line with the ability of CARPs to maintain
mitochondrial function and energy generation, in this
and previous studies R18 was demonstrated to increase
MTS metabolism in uninjured neurons and in neurons
after exposure to glutamic acid [14].
Bioinformatic analysis of the DEPs identified in the
present study largely focused on the 73 proteins up- or
down-regulated by glutamic acid excitotoxic injury.
However, it is important to note that 25 other DEPs
were also identified to be uniquely regulated by com-
bined R18 + Glut treatment, which may represent add-
itional proteins influenced by R18 and associated with
Fig. 7 Cytoscape ClusterONE analysis of enriched STRING protein-protein interaction network of shared DEPs regulated by both Glut and R18 + Glut.
Cytoscape ClusterONE analysis was used to group protein clusters based on their involvement in ‘Mitochondrial respiration’, ‘Axonal growth and
neuronal differentiation’, ‘Transmembrane trafficking’, ‘Endoplasmic reticulum proteostasis’, ‘Glycolysis and carbohydrate metabolism’, ‘Mitochondrial
fatty acid synthesis’, or ‘RNA trafficking and processing’. Clusters represent statistical significance cut-offs of p < 0.05, and empty nodes represent
proteins that do not share statistically significant functions with other proteins
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neuroprotection. Alternatively, these proteins could re-
flect non-specific changes in protein expression unre-
lated to neuroprotection.
Limitations and future directions
The proteomics methodology used in this study does
not provide insight into other forms of protein modifica-
tion, such as post-translational changes (e.g. phosphoryl-
ation, acetylation, and glycosylation), which may
influence protein functions important for neuroprotec-
tion. In addition, only a 24-h timepoint was examined
and therefore it would also be of interest to examine
protein expression changes, as well as post-translational
modifications at earlier timepoints after R18 treatment.
Further studies are also required to confirm if the DEPs
and the biochemical and disease pathways influenced by
R18 treatment after glutamic acid excitotoxicity in vitro
are also affected by the peptide in animal models of
acute brain injury (e.g. stroke, TBI) and chronic neuro-
degenerative disorders (AD, PD).
Conclusion
This exploratory study has demonstrated for the first
time that the poly-arginine peptide R18 exerts significant
effects in attenuating the protein expression changes
associated with neuronal excitotoxicity in vitro, while in-
ducing minimal changes in uninjured neurons. Collect-
ively, our findings indicate that the neuroprotective
effects of R18 following excitotoxicity are associated pre-
dominantly with preservation of neuronal proteostasis,
together with positive effects on mitochondrial and pro-
teasomal function. The findings of this study provide
further evidence supporting the role of poly-arginine
peptides as a potential neuroprotective therapeutic for
both acute and chronic neurodegenerative disorders.
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